Pathogenic UNC13A variants cause a neurodevelopmental syndrome by impairing synaptic function
- PMID: 41125872
- PMCID: PMC12597829
- DOI: 10.1038/s41588-025-02361-5
Pathogenic UNC13A variants cause a neurodevelopmental syndrome by impairing synaptic function
Abstract
The UNC13A gene encodes a presynaptic protein that is crucial for setting the strength and dynamics of information transfer between neurons. Here we describe a neurodevelopmental syndrome caused by germline coding or splice-site variants in UNC13A. The syndrome presents with variable degrees of developmental delay and intellectual disability, seizures of different types, tremor and dyskinetic movements and, in some cases, death in early childhood. Using assays with expression of UNC13A variants in mouse hippocampal neurons and in Caenorhabditis elegans, we identify three mechanisms of pathogenicity, including reduction in synaptic strength caused by reduced UNC13A protein expression, increased neurotransmission caused by UNC13A gain-of-function and impaired regulation of neurotransmission by second messenger signalling. Based on a strong genotype-phenotype-functional correlation, we classify three UNC13A syndrome subtypes (types A-C). We conclude that the precise regulation of neurotransmitter release by UNC13A is critical for human nervous system function.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: A.D.G. is a scientific founder of Trace Neuroscience. N.L. is a member of the scientific advisory board of Trace Neuroscience. S.M., E.M.G. and R.D.M. are employees of Trace Neuroscience. All the above may own stock in Trace Neuroscience. G.O. and A. Rad are employees of Arcensus GmbH. Y.C., K.G.M. and I.M.W. are employees of and may own stock in GeneDx. D. Koeberl has received grant support from Viking Therapeutics, Genzyme Sanofi, Roivant Rare Diseases and Amicus and has held equity in Asklepios Biopharmaceutical (AskBio). The other authors declare no competing interests.
Figures
References
MeSH terms
Substances
Grants and funding
- R01 NS127830/NS/NINDS NIH HHS/United States
- ERC Advanced Grant SynPrime/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
- R01 HG009141/HG/NHGRI NIH HHS/United States
- NE 2118/3-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- R01 NS127830-01A1/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- F31 NS130894/NS/NINDS NIH HHS/United States
- NE 2118/2-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- UM1 HG006493/HG/NHGRI NIH HHS/United States
- U24 HG008956/HG/NHGRI NIH HHS/United States
- PRG471/Eesti Teadusagentuur (Estonian Research Council)
- JP24ek0109617/Japan Agency for Medical Research and Development (AMED)
- NS 116747/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
- K02 NS112600/NS/NINDS NIH HHS/United States
- UM1 HG008900/HG/NHGRI NIH HHS/United States
- (ICGNMD) MR/S005021/1/RCUK | Medical Research Council (MRC)
- EXC-2049-390688087/Deutsche Forschungsgemeinschaft (German Research Foundation)
- TH1538/3-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- HE5415/6-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- He5415/7-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- PRG2040/Eesti Teadusagentuur (Estonian Research Council)
- GNT1113531/Department of Health | National Health and Medical Research Council (NHMRC)
- 424778381 - TRR 295/Deutsche Forschungsgemeinschaft (German Research Foundation)
- S10OD021553/U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD)
- CRC 1286/Deutsche Forschungsgemeinschaft (German Research Foundation)
- R01HG009141/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- R01 NS131512/NS/NINDS NIH HHS/United States
- R01 NS116747/NS/NINDS NIH HHS/United States
- UK MR/J004758/1, G0802760, G1001253 and (ICGNMD) MR/S005021/1/RCUK | Medical Research Council (MRC)
- JP24ek0109760/Japan Agency for Medical Research and Development (AMED)
- JP24ek0109677/Japan Agency for Medical Research and Development (AMED)
- CRC 1286 Project A9/Deutsche Forschungsgemeinschaft (German Research Foundation)
- EZ-2014-226/Einstein Stiftung Berlin (Einstein Foundation Berlin)
- JP24ek0109548/Japan Agency for Medical Research and Development (AMED)
- Operational Infrastructure Support Program/State Government of Victoria (Victorian Government)
- INDO/FRC/452/(Y-83)/2016-17/IHD/Indian Council of Medical Research (ICMR)
- HE5415/3-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- IL-2023-C1-L2/Target ALS (Target ALS Foundation)
- UM1HG008900/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- U01 HG011755/HG/NHGRI NIH HHS/United States
- strategic awards (Synaptopathies) (WT093205MA and WT104033/Z/14/Z)/Wellcome Trust (Wellcome)
- EXC2067/1-390729940/Deutsche Forschungsgemeinschaft (German Research Foundation)
- JP24ek0109674/Japan Agency for Medical Research and Development (AMED)
- HE5415/5-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
- WT_/Wellcome Trust/United Kingdom
- S10 OD021553/OD/NIH HHS/United States
- U01HG011755/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
LinkOut - more resources
Full Text Sources
